Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

Ottawa Hospital Research Institute

$761,175.00

Assessing the site and mechanism of Parkinson's disease initiation in vivo

FY 2016-17

Summary
Parkinson's disease (PD) is an age-related movement disorder whose familiar features of tremor and rigidity result from the loss of neurons in characteristic regions of the brain. There is a growing body of evidence that these symptoms are preceded by other abnormalities that may arise decades before the movement issues become obvious. Notable amongst these abnormalities are a diminished sense of smell and persistent constipation, which are attributable to a loss of function of neurons in the nose and gut respectively. It has been postulated that PD is actually initiated at these sites by the exposure of neurons to some environmental agent (viruses or pesticides, for example) which promotes misfolding of a critical protein in susceptible individuals. The misfolded protein (alpha synuclein) may aggregate and spread from one neuron to another and act as a template to promote the misfolding of additional molecules of alpha synuclein. Over the course of decades the misfolding problem may reach the brain, having traversed neuronal connections from the distant sites of disease initiation. If true, this mechanism would provide a large window of opportunity for interventions to delay or eliminate the disease. We propose to test the hypothesis using a mouse line that we have created specifically for this purpose. We have engineered this line such that the aggregation of the misfolded protein generates a fluorescent signal that can be detected by microscopy. We will use known genetic or environmental triggers to initiate the process, and determine where in the gut or nasal lining the fluorescence is first detected. We will follow the fluorescent signal over time and determine if there is spread to the brain. We will also use clinical samples to determine whether the forms of misfolded alpha synuclein that are present in subtypes of human neurodegenerative disease initiate spread in our mouse model.
Program
Project Grant
Location
Ontario, Canada
Recipient Type
Other
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
355723
Name
Gray Douglas A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Assessing the site and mechanism of Parkinson's disease initiation in vivo
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$761,175
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Alpha Synuclein; Bifluorescent Complementation; Prion Like Spread; Protein Aggregation; Transgenic Mice
Abstract
Parkinson's disease (PD) is an age-related movement disorder whose familiar features of tremor and rigidity result from the loss of neurons in characteristic regions of the brain. There is a growing body of evidence that these symptoms are preceded by other abnormalities that may arise decades before the movement issues become obvious. Notable amongst these abnormalities are a diminished sense of smell and persistent constipation, which are attributable to a loss of function of neurons in the nose and gut respectively. It has been postulated that PD is actually initiated at these sites by the exposure of neurons to some environmental agent (viruses or pesticides, for example) which promotes misfolding of a critical protein in susceptible individuals. The misfolded protein (alpha synuclein) may aggregate and spread from one neuron to another and act as a template to promote the misfolding of additional molecules of alpha synuclein. Over the course of decades the misfolding problem may reach the brain, having traversed neuronal connections from the distant sites of disease initiation. If true, this mechanism would provide a large window of opportunity for interventions to delay or eliminate the disease. We propose to test the hypothesis using a mouse line that we have created specifically for this purpose. We have engineered this line such that the aggregation of the misfolded protein generates a fluorescent signal that can be detected by microscopy. We will use known genetic or environmental triggers to initiate the process, and determine where in the gut or nasal lining the fluorescence is first detected. We will follow the fluorescent signal over time and determine if there is spread to the brain. We will also use clinical samples to determine whether the forms of misfolded alpha synuclein that are present in subtypes of human neurodegenerative disease initiate spread in our mouse model.
Competitiondate
201610
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Gray, Douglas A; Woulfe, John M
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $761,175~ $0~
Ottawa Hospital Research Institute - $761,175 Grant (… | Canada Spends